ALL
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Conference Coverage
TKI choice key for fit/unfit patients with Ph+ALL
Ponatinib (Iclusig) is associated with high response rates in combination therapy, but toxicities may be too great for less fit patients.
From the Journals
CSF metabolomic profile linked to cancer-related fatigue in children with ALL
From the Journals
Polygenic risk score may predict VTE in adolescents, but not adults, with ALL
From the Journals
Posaconazole prophylaxis was effective in children with ALL undergoing chemotherapy
Targeted posaconazole prophylaxis was effective in preventing invasive fungal infection in children with ALL undergoing induction chemotherapy.
Conference Coverage
Inotuzumab / bosutinib treat R/R Ph+ ALL, CML in blast phase
Conference Coverage
HSCT may be best option for therapy-related ALL
Conference Coverage
Omitting whole body irradiation before HSCT: Trial stopped early
“Our study shows significantly better outcomes for total body irradiation compared to myeloablative chemo-conditioning arms.”
Conference Coverage
Risk index stratifies pediatric leukemia patients undergoing HSCT
From the Journals
Acute lymphoblastic leukemia can be successfully treated in the frail elderly
Attenuated chemotherapy shows effectiveness in frail and elderly ALL patients.
Conference Coverage
Universal CAR-T therapy produces CRs in relapsed/refractory T-ALL
All five patients studied achieved a complete response, though one patient had a morphological relapse.